In neurodevelopmental disorders, heterozygous de novo pathogenic variants in EEF1A2 provide strong causal human genetic evidence for developmental and epileptic encephalopathies and related phenotypes, supported by functional studies showing reduced de novo protein synthesis/elongation and altered actin bundling in common patient-associated variants. This evidence concerns the gene EEF1A2 and Epileptic encephalopathy.